The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.03 — distress zone — historically elevated failure riskWatch
- Earnings quality 73/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Sanara MedTech Inc. reports it. History and quarterly detail are in the app.
- Soft Tissue Repair Products$91.3M
- Bone Fusion Products$11.8M
Leadership changes
From Sanara MedTech Inc.'s own filings, the day they're filed.
- Seth D. Yon · President · appointmenteff. 2025-09-15
- Elizabeth B. Taylor · Chief Financial Officer · departureeff. 2025-08-29
- Ronald T. Nixon · Chief Executive Officer · departureeff. 2025-08-27
Latest filings
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-06-09
- 8-K · Company announcement2026-06-04
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Sanara MedTech Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Sanara MedTech Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.